Publikationen 2023
H. Ibrahim, W. Sippl. Editorial "Histone Acetyltransferase and Deacetylase Inhibitors - New Aspects and Developments". Int J Mol Sci. 24(23):16985, 2023. doi:10.3390/ijms242316985 .
H. Ahmed, R. Wallimann, L. Gisler, N. H. Elghazawy, S. Gruber, C. Keller, S. H. Liang, W. Sippl, A. Haider, S. M. Ametamey. Characterization of (R)- and (S)-[18F]OF-NB1 in Rodents as Positron Emission Tomography Probes for Imaging GluN2B Subunit-Containing N-Methyl-D-Aspartate Receptors. ACS Chem Neurosci. 14(24):4323-4334, 2023. doi:10.1021/acschemneuro.3c00519
M T Tavares , A Krüger, S L Rei Yan, K B Waitman, V M Gomes, D Sumam de Oliveira, F Paz, S Hilscher, M Schutkowski, W Sippl, C Ruiz, M F Z J Toledo, N M A Hassimotto, J A Machado-Neto, A Poso, M D Cameron, T D Bannister, G Palmisano, C Wrenger, T Kronenberger, R Parise-Filho. 1,3-diphenylureido hydroxamate: a promising scaffold for generation of potent antimalarial histone deacetylase inhibitors. Sci Rep. 13(1):21006, 2023. doi:10.1038/s41598-023-47959-z .
Korff M, Chaudhary A, Li Y, Zhou X, Zhao C, Rong J, Chen J, Xiao Z, Elghazawy NH, Sippl W, Davenport AT, Daunais JB, Wang L, Abate C, Ahmed H, Crowe R, Schmidt TJ, Liang SH, Ametamey SM, Wünsch B, Haider A. Synthesis and Biological Evaluation of Enantiomerically Pure ( R) - and ( S) -[18F]OF-NB1 for Imaging the GluN2B Subunit-Containing NMDA Receptors. J Med Chem. 66(23):16018-16031, 2023. doi:10.1021/acs.jmedchem.3c01441 .
M. Abdelsalam, M. Zmyslia, K. Schmidtkunz, A. Vecchio, M. Zessin, M. Schutkowski, M. Jung, C. Jessen-Trefzer, W. Sippl. Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells. Arch Pharm (Weinheim). e2300536, 2023. doi:10.1002/ardp.202300536 .
F. Baselious, D. Robaa, W. Sippl. Utilization of AlphaFold Models for Drug Discovery: Feasibility and Challenges. Histone Deacetylase 11 as a Case Study. Comput Biol Med. 167:107700, 2023. doi:10.1016/j.compbiomed.2023.107700
J. Chen, W. Ran, Y. Huang, J. Wei, J. Rong, H. Wei, Y. Li, G. Li, Z. Chen, L. Collier, N. H. Elghazawy, W. Sippl, A. Haider, K. Liao, C. Dong, Y. Li, W. He, L- Wang, S. H. Liang. Development of a novel 18F-labeled positron emission tomography tracer for AMPA receptors imaging. Biomed Pharmacother. 168:115842, 2023. doi:10.1016/j.biopha.2023.115842 .
C.V. Simoben , S.B. Babiaka, A.F.A. Moumbock, C.T. Namba-Nzanguim, D.B. Eni, J.L. Medina-Franco, S. Günther, F. Ntie-Kang, W. Sippl. Challenges in natural product-based drug discovery assisted with in silico-based methods. RSC Adv. 13(45):31578-31594, 2023. doi:10.1039/d3ra06831e
L. Sinatra, A. Vogelmann, F. Friedrich, M. Tararina, E. Neuwirt, A. Colcerasa, P. König, L. Toy, T. Z. Yesiloglu, O. Einsle, W. Sippl, O. Groß, G. Bendas, D. W. Christianson, F. K. Hansen, M. Jung, M. Schiedel. Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation. J Med Chem. 66(21):14787-14814, 2023. doi:10.1021/acs.jmedchem.3c01385
Y. Zeyn, K. Hausmann, M. Beyer, M. Halilovic, H. S. Ibrahim, S. Mahboobi, W. Sippl, O. H. Krämer. Novel Nanomolar HDAC Inhibitors and FLT3 inhibition modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinas. Leukemia 37(11):2319-2323, 2023. doi:10.1038/s41375-023-02036-2
Haider A, Wang L, Gobbi L, Li Y, Chaudhary A, Zhou X, Chen J, Zhao C, Rong J, Xiao Z, Hou L, Elghazawy NH, Sippl W, Davenport AT, Daunais JB, Ahmed H, Crowe R, Honer M, Rominger A, Grether U, Liang SH, Ametamey SM. Evaluation of [18F]RoSMA-18-d6 as a CB2 PET Radioligand in Non-Human Primates. ACS Chem Neurosci. 14(20):3752-3760, 2023. doi:10.1021/acschemneuro.3c00222
M. Schwark, J. A. Martínez Yerena, K. Röhrborn, P. Hrouzek, P. Divoká, L. Štenclová, K. Delawská, F. Wiley, H. Enke, C. Vorreiter, W. Sippl, R. Sobotka, S. Saha, S. B. Wilde, J. Mareš, T. H. J. Niedermeyer. More than just an Eagle Killer: The freshwater cyanobacterium Aetokthonos hydrillicola produces highly toxic dolastatin derivatives. Proc Natl Acad Sci U S A. 120(40):e2219230120, 2023. doi:10.1073/pnas.2219230120 .
S. Hagemann, D. Misiak, J. L. Bell, T. Fuchs, M. I. Lederer, N. Bley, M. Hämmerle, E. Ghazy, W. Sippl, J. H. Schulte, S. Hüttelmaier. IGF2BP1 induces high-risk neuroblastoma and forms a druggable feedforward loop with MYCN promoting 17q oncogene expression. Mol Cancer. 22(1):88, 2023. doi:10.1186/s12943-023-01792-0 .
E. F. Bülbül, D. Robaa, P. Sun, F. Mahmoudi, J. Melesina, M. Zessin, M. Schutkowski, and W. Sippl. Application of ligand- and structure-based prediction models to study the class of alkylhydrazides as HDAC3 inhibitors with anti cancer activity. Pharmaceuticals 16(7), 968, 2023. doi.org/10.3390/ph16070968
H. Nassar, W. Sippl, Wolfgang, R. Abu Dahab, M. Taha. Molecular Docking, Molecular Dynamics Simulations and In Vitro Screening Reveal Cefixime and Ceftriaxone as GSK3β Covalent Inhibitors. RSC Adv. 13, 11278-11290, 2023. DOI:10.1039/D3RA01145C
M. A. Fischer, A. M. Mustafa, K. Hausmann, R. Ashry, C. Brachetti, A. Piée-Staffa, M. Zessin, H. S. Ibrahim, M. Schutkowski, W. Sippl, O. H. Krämer. Novel Hydroxamic Acid Derivative induces Apoptosis and constrains Autophagy in Leukemic Cells. J Adv Res. 17:S2090-1232(23)00197-2, 2023. doi:10.1016/j.jare.2023.07.005 .
A. Haider, N.H. Elghazaw, A. Dawood, C. Gebhard, T. Wichmann, W. Sippl, M. Hoener, E. Arenas, S.H. Liang. Translational molecular imaging and drug development in Parkinson's disease. Mol Neurodegener. 18(1):11, 2023. doi:10.1186/s13024-023-00600-z.
L. Seitz, N. Reiling, C. Vorreiter, W. Sippl, S. Kesselr, A. Hilgeroth. Synthesis and Evaluation of Novel Substituted N-Aryl 1,4-Dihydropyridines as An-tituberculostatic Agents. Med Chem. 2023 Jun 22. doi:10.2174/1573406419666230622121512
S. Wimmer, K. Hoff, B. Martin, M. Grewer, L. Denni, R. L. Massanet, E. F. Bülbül, J. Melesina, P. Haffke, M. V. Raimondi, H. Rohde, W. Sippl, and R. Holl. Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors. Bioorg Chem. 131:106331, 2023. doi.org/10.1016/j.bioorg.2022.106331
S. Darwish, T. Heimburg, J. Ridinger, D. Herp, M. Schmidt, C. Romier, M. Jung, I. Oehme, W. Sippl. Synthesis, Biochemical and Cellular Evaluation of HDAC6 targeting proteolysis targeting chimeras (PROTAC). Methods Mol Biol. 2589:179-193, 2023. doi:10.1007/978-1-0716-2788-4_12 .
M. Abdelsalam, H. S. Ibrahim, L. Krauss, M. Zessin, A. Vecchio, S. Hastreiter, M. Schutkowski, G. Schneider, W. Sippl. Development of pyrazine-anilinobenzamides as histone deacetylase HDAC1-3 selective inhibitors and biological testing against pancreas cancer cell lines. Methods Mol Biol. 2589:145-155, 2023. doi:10.1007/978-1-0716-2788-4_10
M. Zessin, M. Meleshin, W. Sippl, M. Schutkowski. Continuous Histone Deacylase Activity Assays. Methods Mol Biol. 2589:411-428, 2023. doi:10.1007/978-1-0716-2788-4_27 .
E. P. Guerra-Slompo, G. F. A. Picchi-Constante, M. Marek, C. Romier, W. Sippl and N. I. T. Zanchin. In cellulo and in vivo assays for compound testing against Trypanosoma cruzi. STAR Protocols 4 (1), 102058, 2023. doi:10.1016/j.xpro.2023.102058 .